Research from JAMA Dermatology — Treatment of Venous Malformations With Sclerosant in Microfoam Form

Venous ulcers constitute approximately 80% of all leg ulcers. Venous leg ulcers have been estimated to afflict 0.2% to 1% of the total population and 1% to 3% of the elderly population in the United States and Europe.¹ Venous ulceration (VU) is a debilitating problem associated with a major financial burden, including medical care costs and the considerable loss of work hours. The treatment of venous ulcers has been estimated to represent 1.3% of the total United Kingdom health care budget.²